^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    2d
    GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    3d
    Tubal epithelial alterations: evolving concepts. (PubMed, J Gynecol Oncol)
    These findings underscore the complexity and heterogeneity of tubal epithelial alterations and suggest that not all lesions follow a linear tumorigenic sequence. Continued integration of morphological, molecular, and spatial analyses will be essential for refining our understanding of tubal pathology and its contribution to gynecological carcinogenesis.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    7d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    8d
    GLORIOSA: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, AbbVie | Trial primary completion date: May 2032 --> Apr 2027
    Trial primary completion date • Platinum sensitive
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    8d
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    lorigerlimab (MGD019)
    9d
    DUAL-OV-CAR-NK: Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    FOLR1 ( Folate receptor alpha ) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    cyclophosphamide • fludarabine IV
    12d
    Association of SNHG17/CDKN2B-AS1 polymorphisms with salpingitis and fallopian tube carcinoma susceptibility in the Chinese Han population. (PubMed, Gynecol Pelvic Med)
    However, no significant associations were found between these SNPs and salpingitis susceptibility. Given the genetic heterogeneity among Han Chinese populations across different regions, these findings from a single center in Sichuan should be validated in multi-regional cohorts to generalize their applicability.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SNHG17 (Small Nucleolar RNA Host Gene 17)
    15d
    BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells. (PubMed, Neoplasia)
    Inhibition of NFκB activation or IFN-I signaling decreased elevated levels of IFN-I-stimulated genes with no further inhibition provided by combining inhibitors. These findings indicate that BRCA1 deficiency preferentially enhances proinflammatory IFN-I signaling in an NFκB-permissive manner and support further investigation of targeting PRR signaling in FTE cells as a potential strategy to mitigate the risk of HGSTOC in BRCA1 mutation carriers.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • STING (stimulator of interferon response cGAMP interactor 1) • STAT2 (Signal transducer and activator of transcription 2) • USP18 (Ubiquitin Specific Peptidase 18)
    |
    BRCA1 mutation
    15d
    IMGN853-0425: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine (clinicaltrials.gov)
    P2, N=110, Recruiting, AbbVie | Trial primary completion date: Mar 2028 --> Jul 2026
    Trial primary completion date • Adverse events • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    Elahere (mirvetuximab soravtansine-gynx)
    15d
    GLORIOSA: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2027 --> May 2032
    Enrollment closed • Trial primary completion date • Platinum sensitive
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    19d
    PIPACOVA: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Hospices Civils de Lyon | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride
    21d
    PROMPT: Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov)
    P2, N=20, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date • Platinum resistant
    |
    Keytruda (pembrolizumab) • paclitaxel